34.3 F
New York
Saturday, October 31, 2020

Is Now the Time to Invest in Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)?

Must read

Investor Confidence is Falling for Borqs Technologies Inc. (NASDAQ:BRQS)

Borqs Technologies Inc. (BRQS) shares are trading at lower $0.96. To add more color to this target, the company’s high over the last year...

The Unprecedented Rise of Church & Dwight Co. Inc. (NYSE:CHD)

Church & Dwight Co. Inc. (CHD) shares are trading at lower $87.06 and the avg recommendation for the stock is Moderate Buy, while the...

Westwater Resources Inc. (NASDAQ:WWR) is Holding Steady

Westwater Resources Inc. (WWR) shares are trading at higher $4.16. To add more color to this target, the company’s high over the last year...

The Forecast Just Changed on Brookdale Senior Living Inc. (NYSE:BKD)

Brookdale Senior Living Inc. (BKD) shares are trading at lower $3.00 and the avg recommendation for the stock is Moderate Buy, while the current...

Sonnet BioTherapeutics Holdings Inc. (SONN) shares are trading at higher $2.97 and the avg recommendation for the stock is Moderate Buy.

To add more color to this target, the company’s high over the last year is $54.60 and the low is $2.23. Over the last 52 weeks, SONN is down -85.62% while the S&P 500 is up 18.03%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

Find out when SONN reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. SONN has a short ratio of 0.32 and outstanding shares of 13.20M.

Company Outlook

SONN has seen increased volume after this news and investors are putting their support behind the value proposition. Traders will also note the company’s earnings per share came in at -34.55. Sonnet BioTherapeutics Holdings Inc. SONN also noted assets of $3.88 million at the end of the last quarter. Investors should also keep an eye on sector updates as SONN has historically followed its peers on positive news.

All told, Sonnet BioTherapeutics Holdings Inc. SONN has strung together solid data and demonstrated underlying fundamentals. At its current valuation, SONN represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Sonnet BioTherapeutics Holdings Inc. SONN is now commanding a market cap of 39.20M and a float of 12.95M. SONN is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of SONN stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in SONN, either long or short, and we have not been compensated for this article.

Latest article

Curaleaf Holdings Inc (OTCMKTS:CURLF) Soars As The Company Launches New Product

Despite the troubles of many cannabis stocks in recent times, Curaleaf Holdings Inc (OTCMKTS:CURLF) stock managed to emerge as one of the...

Why Tencent Holdings ADR (OTCMKTS:TCEHY) has been Thrust into the Spotlight

Chinese technology conglomerate Tencent Holdings ADR (OTCMKTS:TCEHY) has been in focus this month among investors, and that has led to a healthy...

Very Good Food Company Inc (OTCMKTS:VRYYF) Hits New High On Renewed Optimism

One of the stocks to have come into focus over the past two weeks is Very Good Food Company Inc (OTCMKTS:VRYYF).

Is Now the Time to Invest in Pilgrim’s Pride Corporation (NASDAQ:PPC)?

Pilgrim's Pride Corporation (PPC) shares are trading at higher $16.27 and the avg recommendation for the stock is Moderate Buy, while the current analyst...

Kontoor Brands Inc. (NYSE:KTB) Stock is Soaring, Here is Why

Kontoor Brands Inc. (KTB) shares are trading at higher $34.75 and the avg recommendation for the stock is Moderate Buy, while the current analyst...